Merrill retains Alizyme at buy

Alizyme was kept at a buy rating by Merrill Lynch analyst Erica Whittaker after the company completed discussions with the Food and Drug Administration on its phase 3 program for approval of its obesity drug cetilistat (ATL-962). A one-year trial program of 4,000 patients is required. The analyst believes that Alizyme will be able to complete a lucrative licensing deal for cetilistat with a pharma partner by early 2007. Shares of the Cambridge, U.K.-based medical device company were down 50p, or 0.50%, at 100p. (LSE: AZM)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.